Video: The Importance of Charitable Patient Assistance Foundations
Charitable patient assistance foundations do crucial work to help individuals access necessary health care.
At this year’s Healthcare Advocate Summit, Drug Topics sat down with Kevin Hagan, President and CEO of the PAN Foundation, to discuss the importance of charitable patient assistance foundations in today’s health care landscape.
“Events like the Healthcare Advocate Summit are critically important because in many cases, outside of the patient, this is our audience,” Hagan said. “These are the people who are working for patients every single day, trying to ensure that they have access to the health care that they need, and that they deserve.”
Watch the full interview below, and be sure to check back later for our coverage of the full panel discussion between Hagan and other leaders in the charitable patient assistance space.
Psychedelic Therapeutics: Education, Advocacy Key to Overcoming Integration Hurdles
March 26th 2024According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.
Pharmacists Should Take a Proactive Approach When Addressing Controlled Substance Concerns
March 24th 2024At this year’s American Pharmacists Association Annual Meeting & Exposition, Mark Garofoli urged pharmacists to develop strong documentation practices and go beyond baseline federal regulations to care for patients with red flags.
How Emotional Intelligence Helps Pharmacists Handle Controlled Substance Concerns
March 23rd 2024Pharmacists must uphold their “corresponding responsibility” to address controlled substance concerns among patients while balancing safety and respect, said Mark Garofoli at this year’s American Pharmacists Association Annual Meeting & Exposition.
How Co-Pay Accumulators, Maximizers Disrupt Patient Access to Care
January 9th 2024In this conversation from the Healthcare Advocate Summit, Ned Woody, associate director of field reimbursement at Daiichi Sankyo Inc. - Oncology, discusses the disruptive impact that these programs have on patients.
